VAIF [Inactivated Split Influenza Vaccine] combines 6 antigens (surface and internal) of influenza virus subtype A (H1N1), subtype A (H3N2) and type B. A highly purified vaccine in phosphate buffered saline.
The main characteristics of the VAIF ingredients and the quality indicator is their ability to develop an effective immune response against strains of great epidemiological importance circulated in the world. During the technological process of production, optimal manufacturing conditions have been adapted to:
1) Maintain stable protective qualities of antigens necessary to ensure effective interaction of antigens and cells and preserve the so-called «confirmatory protective epitopes».
2) Manufacture a pharmaceutical product that complies with all international requirements. Hemagglutinin protein is a key protective antigen. Hemagglutinin is an integral membrane protein with a tendency to aggregation.
Highly purified low reactogenicity antigens are used to make VAIF. The vaccine has a relatively low level of adverse effects, its characteristics of immunobiological activity comply with international requirements for influenza vaccines and guarantee immunity against influenza after its application.
| Content | Contents per one dose | Function |
Active ingredients |
||
| Hemaglutinina А (H1N1) |
15 mcg |
Antígeno (ingrediente activo) |
| Hemaglutinina А (H3N2) |
15 mcg |
|
| Hemaglutinina tipo В | 15 mcg |
|
Auxiliary substances: |
||
| Tiomersal | 50 mcg |
Preservante (multi dosis) |
| - | - | Sin preservantes (una dosis) |
| Tampón fosfato salino | Hasta 0,5 ml |
Diluyente |
